Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ISRCTN71771495) titled 'EValuating the efficacy Of upadacitinib and combination upadacitinib pLus risankizumab for the treatment of fistulising perianal Crohn's Disease - an open-label Phase IV a randomisEd controlled trial' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Open (masking not used)
Control: Active
Assignment: Parallel
Purpose: Treatment, Safety
Primary Sponsor: Imperial College London
Condition:
Fistulising perianal Crohn's disease (fpCD)
Digestive System
Intervention:
Participants will be randomised in a 1:1 ratio using the Sealed Envelope randomisation system ...